论文部分内容阅读
目的探讨文拉法辛缓释片治疗对癫痫性抑郁障碍患者血清DA、5-HT和炎症因子水平的影响。方法收集2013年1月~2015年12月期间我院收住的癫痫性抑郁障碍患者92例,按照随机数字表法随机分为观察组46例与对照组46例。在抗癫痫药物治疗的基础上,对照组加用盐酸氟西汀胶囊治疗,观察组加用文拉法辛缓释片治疗,两组疗程均为8周。观察比较两组患者治疗前后血清DA、5-HT和炎症因子水平。结果 (1)治疗前后两组患者的HAMA和HAMD评分差异均无统计学意义(P>0.05);且治疗后两组患者的评分均较治疗前明显降低(P<0.05);(2)与治疗前相比,治疗后两组患者血清DA和5-HT水平明显升高,IL~(-1)β和IL-4水平明显降低(P<0.05);且与对照组相比,治疗后观察组患者的血清5-HT水平明显升高,IL~(-1)β和IL-4水平明显降低(P<0.05);(3)两组均未见严重药物不良反应。结论文拉法辛缓释片治疗癫痫性抑郁障碍患者疗效显著,与氟西汀相当,其可能通过升高5HT水平、降低IL~(-1)β和IL-4水平来发挥作用。
Objective To investigate the effects of venlafaxine extended-release tablets on serum DA, 5-HT and inflammatory cytokines in patients with epilepsy and depression. Methods Ninety-two patients with epilepsy depression admitted in our hospital from January 2013 to December 2015 were randomly divided into observation group (n = 46) and control group (n = 46) according to the random number table method. On the basis of anti-epileptic drug treatment, the control group plus fluoxetine hydrochloride capsule treatment, the observation group plus venlafaxine sustained-release tablets treatment, the two groups were treated for 8 weeks. The levels of serum DA, 5-HT and inflammatory cytokines in the two groups before and after treatment were observed and compared. Results (1) There was no significant difference in HAMA and HAMD scores between the two groups before and after treatment (P> 0.05). After treatment, the scores of both groups were significantly lower than those before treatment (P <0.05) Compared with the control group, the levels of serum DA and 5-HT in the two groups were significantly increased and the levels of IL-1β and IL-4 were significantly decreased after treatment (P <0.05). Compared with the control group, after treatment The level of serum 5-HT in the observation group was significantly increased, the levels of IL-1β and IL-4 were significantly decreased (P <0.05). (3) No serious adverse drug reactions were observed in both groups. Conclusions Venlafaxine sustained-release tablets have a significant therapeutic effect on patients with epilepsy and depressive disorder, which is equivalent to fluoxetine, which may play a role in raising the level of 5HT and decreasing the levels of IL-1β and IL-4.